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A B S T R A C T
Purpose
To examine cancer genes undergoing epigenetic inactivation in a set of T-cell acute lymphoblas-
tic leukemias (T-ALLs) to obtain the CpG island methylator phenotype (CIMP) in the disease and
its possible correlation with clinical features and outcome of the patients.
Patients and Methods
Methylation-specific polymerase chain reaction was used to analyze methylation of the
ADAMTS-1, ADAMTS-5, APAF-1, ASPP-1, CDH1, CDH13, DAPK, DIABLO, DKK-3, LATS-1,
LATS-2, NES-1, p14, p15, p16, p57, p73, PARK-2, PTEN, sFRP1/2/4/5, SHP-1, SYK, TMS-1,
and WIF-1 genes in samples from 50 consecutive T-ALL patients (19 children and 31
adults). Results were compared with results obtained in 286 B-cell acute lymphoblastic
leukemias (B-ALLs).
Results
A total of 88% of the T-ALL samples had at least one gene methylated. According to the
number of methylated genes observed in each individual sample, 12 patients (24%) were
included in the CIMP group (zero to two methylated genes), and 38 patients (76%) were
included in the CIMP group ( two methylated genes). Clinical features and remission rate
did not differ significantly among both groups of patients. Estimated disease-free survival
(DFS) rate at 12 years and overall survival (OS) rate at 13 years were 100% and 91% for
the CIMP group and 20% and 17% for the CIMP group, respectively (P  .0006 and
P  .003, respectively). Multivariate analysis demonstrated that methylation profile was an
independent prognostic factor in predicting DFS (P  .05) and OS (P  .02). A group of five
genes (SYK-1, ASPP-1, sFRP-2, sFRP-5, and WIF-1) showed specificity for T-ALL compared
with B-ALL.
Conclusion
Our results suggest that the methylation profile may be a potential new biomarker of risk
prediction in T-ALL.
J Clin Oncol 23:7043-7049. © 2005 by American Society of Clinical Oncology
INTRODUCTION
On the basis of the expression of lineage-
specific antigens and the presence of
lineage-specific gene rearrangements, acute
lymphoblastic leukemia (ALL) cells are
known to be derived from either B- or T-cell
precursors.1 T-lineage ALLs (T-ALLs) are
associated with distinctive biologic behavior
and clinical features and, historically, have
had a worse prognosis when compared with
precursor B-lineage ALLs (B-ALLs). Indeed,
20% to 50%of patients with T-ALL die from
progressive disease.2 Although these out-
comes constitute a marked improvement
relative to 30 years ago, complete remission
(CR) rates and overall survival (OS) have
improved only slightly over the last decade.2
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The development of reliable laboratory tests that pre-
dict patient prognosis may lead to enhanced patient sur-
vival. In B-ALL, malignant cells often have additional
specific genetic abnormalities, which have a significant im-
pact on the clinical course of the disease. In contrast, few
molecular abnormalities have been detected in T-ALL, and
no cytogenetically defined prognostic subgroups have been
identified. Moreover, compared with patients with
B-ALL, the clinically important features of age at diagno-
sis, WBC count, and degree of bulky, lymphomatous
disease are much less efficient predictors of outcome for
patients with T-ALL when treated with modern aggres-
sive chemotherapy.3,4 Therefore, useful molecular mark-
ers for risk-specific adjustments in therapeutic intensity
are necessary in this disease.
DNA methylation is an essential mechanism for the
regulation of gene expression in mammalian cells.5 Meth-
ylation occurs at cytosine residues within CpG dinucleo-
tides, andmany genes are enriched with these dinucleotides
in their promoters. These regions are known as CpG islands
and are generally nonmethylated, a condition that allows
genes to be transcriptionally competent. Methylation of
CpG islands within gene promoters leads to transcriptional
silencing through recruitment of methyl-CpG–binding
protein and histone deacetylases.6,7 Hence, identification of
themethylation patterns ofCpG islands inmammalian cells
is important for understanding normal and pathologic gene
expression. Several reports have shown that abnormal hy-
permethylation of CpG islandsmay contribute significantly
to the pathogenesis of human leukemias, providing an al-
ternative route to gene mutation of cancer-related genes.
We have recently shown that the methylation of cytosine
nucleotides in ALL cells can help to inactivate tumor-
suppressive apoptotic or growth-arresting responses and
has prognostic impact in B-ALL.8 The presence in individ-
ual tumors of multiple genes simultaneously methylated (a
condition termed CpG island methylator phenotype
[CIMP]) is an independent factor of poor prognosis in
both childhood and adult B-ALL in terms of disease-free
survival (DFS) and OS. Moreover, methylation status was
able to redefine the prognosis of selectedB-ALL groupswith
well-established prognostic features. Lack of CIMP (CIMP)
improved the general poor outcome of patients presenting
with the Philadelphia chromosome or high WBC count at
diagnosis, whereas presence of methylation worsened the
general good outcome of TEL-AML1–positive patients. To
determine whether methylation profiles are also of clinical
relevance in T-ALL, we have examined multiple key cancer
genes undergoing epigenetic inactivation in a set of de novo
T-ALLs with the aim of obtaining amap of this alteration in
the disease and its possible correlation with clinical features
and outcome of the patients.
PATIENTS AND METHODS
Patients
We studied 50 consecutive patients (37males and 13 females)
with de novo T-ALL who were enrolled onto successive multi-
center studies of the “Programa para el Estudio y Tratamiento de
las Hemopatias Malignas” (PETHEMA) Spanish study group. All
of these patients were referred to the Reina Sofia Hospital of
Cordoba, Spain, from January 1990 to December 2003. The me-
dian age at diagnosis in the study population as a whole was 21
years (range, 3 to 56 years). Of these patients, 19 were children
(median age, 9 years; range, 3 to 14 years), and 31 were adults
(median age, 28 years; range, 15 to 56 years). The study was
approved by the investigational review boards in accordance with
the policies of the Department of Health and Human Services.
Informed consent was obtained from the patient or the patient’s
guardians. Diagnosis was established according to standard
morphologic, cytochemical, and immunophenotypic criteria. Im-
munophenotypic analysis was performed using monoclonal anti-
bodies specific for the following antigens: TdT, HLA-DR, CD7,
CD19, CD22, CD10, CD14, CD33, CD13, CD61, CD34, CD2,
myeloperoxidase, and surface CD3. For further characterization,
expression of the following panel of T-cell–associated antigenswas
used to establish the degree of differentiation of leukemic blasts:
cytoplasmic CD3, CD5, CD1a, CD4, and CD8; samples were clas-
sified according to the criteria of the European Group of Immu-
nological Characterization of Leukemia.9 After diagnosis, patients
were entered onto ALL protocols for high-risk patients of the
PETHEMA Spanish study group. The specific PETHEMA ALL
treatment protocols in which these patients entered included
ALL-89 (between 1990 and 1992; n 8) and ALL-93 (between 1993
and 2003; n 42). The design and results of these studies have been
previously reported.10-13 Twenty-seven patients relapsed. Fifteen pa-
tients received stem-cell transplantation (five autologous and 10 allo-
geneic) in the first (n  5) or second (n  10) CR. There are 21
patients currently alive. Clinical characteristics of the patients are
listed in Table 1. In addition, we also studied 286 consecutive B-ALL
patients diagnosed during the same period of time to compare the
methylation profiles of both T- and B-ALL.
Gene Selection
Bone marrow specimen was obtained from all the patients at
the moment of diagnosis. High molecular weight DNA was pre-
pared from mononuclear diagnostic marrow cells using conven-
tional methods, frozen at80°C, and retrospectively analyzed to
assess the role ofmethylation profile. In all the cases, the diagnostic
bone marrow sample contained blast cells in the ratio of at least
70%.We studied 27 genes belonging to all of the followingmolec-
ular pathways involved in cell immortalization and transforma-
tion: cell cycle (p15, p16, p57, and LATS-2), cell adherence and
metastasis process (CDH1, CDH13, ADAMTS1, and ADAMTS5),
p53 network (p14, p73, and ASPP-1), apoptosis (TMS1, APAF-1,
DAPK, andDIABLO), inhibitors of the oncogenic WNT signaling
pathway (DKK-3, WIF-1, sFRP-1, sFRP-2, sFRP-4, and sFRP-5),
differentiation regulation (NES-1), ubiquitination (PARK-2), ty-
rosine kinase with an essential role in signal transduction (SYK),
negative regulator of the Jak/STAT signaling pathway (SHP-1),
and main tumor-suppressor genes (LATS-1 and PTEN; Table 2).
Different criteria were used for gene selection. CDH1, p73, p16,
p15, p57, NES-1, DKK-3, CDH13, p14, TMS1, APAF-1, DAPK,
PARKIN, LATS-1, and PTEN were selected because of their
frequent methylation in ALL.8 The other genes were studied
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because they have been found to bemethylated in othermalignan-
cies, including leukemic cell lines, and their abnormal expression
could have potentially important roles in ALL.14-21 The regions
where these genes reside are not prone to mutations, deletions, or
rearrangement in the majority of human leukemias; however,
microsatellitemarkers from these regions have shown thatmost of
them are common sites for loss of heterozygocity inALL.23 Each of
these genes possesses a CpG island in the 5 region, which is
normally unmethylated in corresponding normal tissues as ex-
pected for a typical CpG island. We and others have shown in
previous studies for such genes in individual tumor types that,
when these CpG islands are hypermethylated in cancer cells,
expression of the corresponding gene is silenced and the silenc-
ing can be partially relieved by demethylation of the promoter
region.8,14-21 For all these genes, we have analyzed at least 10
normal marrow and peripheral-blood specimens, none of
which showed significant methylation.
Methylation-Specific Polymerase Chain Reaction
Aberrant promoter methylation of these genes was deter-
mined by method of methylation-specific polymerase chain reac-
tion (MSP) as reported by Herman et al.24 MSP distinguishes
unmethylated alleles of a given gene based on DNA sequence
alterations after bisulfite treatment of DNA, which converts un-
methylated but not methylated cytosines to uracils. Subsequent
polymerase chain reaction using primers specific to sequences
corresponding to either methylated or unmethylated DNA se-
quences was then performed. Primer sequences of each gene for
the unmethylated and methylated reactions have been reported
elsewhere.8,14-21 Hot start polymerase chain reaction was per-
formed for 30 cycles consisting of denaturation at 95°C for 1
minute, annealing at 60°C for 1 minute, and extension at 72°C for
1 minute, followed by a final 7-minute extension for all primer
sets. The products were separated by electrophoresis on 2% aga-
rose gel. Bone marrow DNA from healthy donors was used as
negative control for methylation-specific assays. Human male
genomic DNA universally methylated for all genes (Intergen
Company, Purchase, NY) was used as a positive control for meth-
ylated alleles. Water blanks were included with each assay. The
presence of a clearly visible band in the MSP using primers for the
methylated alleles was considered as a positive result for methyl-
ation. This result was always confirmed by repeatMSP assays after
an independently performed bisulfite treatment. In the sporadic
cases where only faint bands were observed in both analyses,
methylation results were validated by Southern blot and/or se-
quencing and/or association with lack of expression assessed by re-
verse transcriptase polymerase chain reaction, as appropriate. The
sensitivity of this MSP was established by using totally methylated,
positive control DNA serially diluted by normal lymphocyte DNA.
MSPs with 1:10, 1:100, and 1:1,000 diluted positive control DNA
produced detectable methylated bands (data not shown).
Statistical Analysis
For statistical purposes, T-ALL patients were classified into
twodifferentmethylation groups; patients showingmethylation at
three or more loci were defined as CIMP, whereas patients in
whom methylation was low (occurring at two or fewer loci) were
defined as CIMP. P values for comparisons of continuous vari-
ables between groups of patients were two tailed and based on the
Wilcoxon rank sum test. P values for dichotomous variables were
based on the Fisher’s exact test. The remaining P values were based
on the Pearson 2 test. OS wasmeasured from the day of diagnosis
until death from any cause and was censored only for patients
known to be alive at last contact. DFS was measured from the day
that CR was established until either relapse or death without
relapse, and it was censored only for patients who were alive
without evidence of relapse at the last follow-up. Distributions of
OS and DFS curves were estimated by the Kaplan-Meier method,
with 95%CIs calculated bymeans of Greenwood’s formula. Com-
parisons of OS or DFS between groups were based on the log-rank
test. Comparisons adjusted for significant prognostic factors were
based onCox regressionmodels and hazard regressionmodels. All
relapse and survival data were updated in December 2004, and all
follow-up data were censored at that point.
RESULTS
Frequency of Methylation in T-ALL
Gene methylation frequencies varied from 7% to 59%.
The following 22 genes demonstrated a relatively high fre-
quency of aberrant methylation: NES-1 (59%), ADAMTS5
Table 1. Clinical Characteristics and Outcome of 50 T-ALL Patients
According to Gene Methylation Status
Characteristic
% of Patients
P
CIMP
(n  12)
CIMP
(n  38)
Age NS
Younger than 15 years 25 75
Older than 15 years 20 80
Sex NS
Male 64 72
Female 36 28
WBC count NS
 50  109/L 40 42
 50  109/L 60 58
Immunophenotype NS
T1 0 6
T2 50 53
T3 25 30
T4 10 5
Incomplete 15 6
BMT 25 31 NS
Treatment NS
PETHEMA 89 17 16
PETHEMA 93 83 84
Best response, CR 91 88 NS
Cytogenetics NS
Normal 40 50
Not assessable 20 20
14q11 10 20
del (6q) 10 0
del (7q) 10 0
Other 10 10
Relapse 0 68  .0001
Death 9 70  .0001
Abbreviations: T-ALL, T-cell acute lymphoblastic leukemia; CIMP,
patients with zero to two CpG island methylated genes; CIMP, patients
with more than two CpG island methylated genes; NS, not significant;
BMT, bone marrow transplantation; PETHEMA, Programa para el Estudio
y Tratamiento de las Hemopatias Malignas; CR, complete remission.
Methylation Profile in T-ALL
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(57%), WIF-1 (53%), sFRP-1 (51%), SYK (49%), CDH1
(47%), ADAMTS1 (43%), CDH13 (43%), APAF-1 (40%),
DKK-3 (40%), LATS-1 (40%), sFRP-5 (40%), PARK-2
(37%), ASPP-1 (34%), sFRP-2 (33%),DIABLO (32%), p14
(27%), p57 (27%), LATS-2 (26%), p73 (26%), PTEN
(20%), and sFRP-4 (20%). Five genes (p15, SHP-1, p16,
TMS-1, andDAPK) showed a low frequency (7% to 18%) of
methylation (Table 3). No methylated genes were found in
six (12%) of 50 patients, whereas most patients with T-ALL
(44 of 50 patients; 88%) hadmethylation of at least one gene
(range, one to 18 methylated genes). No patient was found
to have methylation of more than 18 genes. According to
the number of methylated genes observed in each individ-
ual sample, 12 patients (24%) were included in the CIMP
group (zero to two methylated genes), and 38 patients
(76%) were included in the CIMP group ( two methyl-
ated genes). Although the presence of CIMP phenotype
was similarly distributed between children (75%) and
adults (80%), significant differences were found in the
methylation status of individual genes between both age
groups; p15 (P .05), p57 (P .03), and PTEN (P .05)
genes were more frequently methylated in adult ALL pa-
tients than in childhood ALL patients. Figure 1 illustrates
representative examples of the methylation patterns of the
most frequently methylated genes.
Comparative analysis of the methylation frequencies
between T-ALL and B-ALL classifies the 27 genes examined
into two groups. The first group is the group of genes
showing significantly higher frequencies of methylation in
T-ALL compared with B-ALL (SYK-1, ASPP-1, sFRP-2,
sFRP-5, andWIF-1; Table 3). The second group is the group
of genes demonstrating similar frequency of methylation in
both subtypes of ALL (the remaining 22 genes). Further-
more, there was more global methylation in T-ALL than in
B-ALL. In fact, 76% of T-ALL patients were CIMP com-
pared with 60% of B-ALL patients (P .03).
Clinical Outcome of T-ALL and
Methylation Profile
As shown in Table 1, clinical and laboratory character-
istics did not differ significantly between methylation
groups. Median age (CIMP: median, 18 years; range, 3 to
56 years; CIMP: median, 21 years; range, 3 to 46 years),
type of PETHEMA protocol administered, and number of
patients who received stem-cell transplantation were simi-
larly distributed among both CIMP groups.
Table 1 also details the relapse history, CR rates, and
mortality for patients included in the different methylation
groups. CR rates of patients in the CIMP and CIMP
groups were 91% and 88%, respectively, accounting for
Table 2. Genes Studied for Methylation in T-ALL
Gene Location Function Reference for MSP Primers
ADAMTS1 21q21.2 Metalloprotease Dunn et al15
ADAMTS5 21q21.3 Metalloprotease Dunn et al15
APAF-1 12q23 Apoptosis regulation Roman-Gomez et al8
ASPP-1 14q32-33 p53 costimulator; apoptosis regulation Mori et al16
CDH1 16q22 Cell-cell adhesion Roman-Gomez et al8
CDH13 16q24 Cell-cell adhesion Roman-Gomez et al22
DAPK 9q34 Apoptosis regulation Roman-Gomez et al8
DIABLO 12q24.31 Apoptosis regulation Mizutani et al17
DKK-3 11p15 Wnt signaling pathway antagonist Roman-Gomez et al8
LATS-1 6q23-25 TSG; G2-M cell-cycle control Roman-Gomez et al8
LATS-2 13q11-12 G1-S cell-cycle control Li et al14
NES-1 19q13 Growth and differentiation control Roman-Gomez et al8
P14 9p21 Cell-cycle control; apoptosis regulation Roman-Gomez et al8
P15 9p21 G1-S cell-cycle control Roman-Gomez et al8
P16 9p21 TSG; G1-S cell-cycle control Roman-Gomez et al8
P57 11p15 G1-S cell-cycle control Roman-Gomez et al8
P73 1p36 G1-S cell-cycle control Roman-Gomez et al8
PARK-2 6q25-27 Ubiquitination Roman-Gomez et al8
PTEN 10q23 TSG; cell adhesion/motility; apoptosis; angiogenesis; G1 cell-cycle regulation; signal transduction Roman-Gomez et al8
sFRP-1 8p12-11.1 Wnt signaling pathway antagonist Lee et al19
sFRP-2 4q31.3 Wnt signaling pathway antagonist Lee et al19
sFRP-4 7p14.1 Wnt signaling pathway antagonist Lee et al19
sFRP-5 10q24.1 Wnt signaling pathway antagonist Lee et al19
SHP-1 12p13 Jak/STAT signaling pathway inhibitor Chim et al21
SYK 9q22 Signal transduction Goodman et al20
TMS-1 16p11-12 Apoptosis regulation Roman-Gomez et al8
WIF-1 12q14.3 Wnt signaling pathway antagonist Mazieres et al18
Abbreviations: T-ALL, T-cell acute lymphoblastic leukemias; TSG, tumor-suppressor gene.
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90% of the overall CR rate. This suggests that methylation
profile did not correlate with response to remission induc-
tion therapy. However, patients in the CIMP group had a
lower relapse rate than patients in the CIMP group (0% v
68%, respectively; P .0001). Mortality rate was also lower
for the CIMP group compared with the CIMP group
(9% v 70%, respectively; P  .0001). Similar results were
obtained in the separate analyses of children (relapse rate,
0% for CIMP group v 58% for CIMP group, P  .05;
mortality rate, 20% for CIMP group v 59% for CIMP
group, P  .05) and adults (relapse rate, 0% for CIMP
group v 78% for CIMP group, P  .007; mortality rate,
0% for CIMP group v 83% for CIMP group, P .004).
We analyzed theDFS among patients who achievedCR
according to themethylation profile. EstimatedDFS rates at
12 years were 100% and 20% for the CIMP and CIMP
groups, respectively (P .0006; Fig 2A). Estimated cumu-
lative incidence of relapse was 0% for the CIMP group
and 80% at 50 months for the CIMP group (P .0001).
The actuarial OS at 13 years calculated for all leukemic
patients was 91% for CIMP patients and 17% for CIMP
patients (P .003; Fig 2B).
A multivariate analysis of potential prognostic factors
demonstrated that hypermethylation profile was the only in-
dependent prognostic factor predicting for DFS (P  .05).
Methylation status was also independently associated withOS
in the global series (P .02; Table 4).
DISCUSSION
Epigenetic gene silencing is increasingly being recognized as
a common way in which cancer cells inactivate cancer-
related genes.5-8 In addition to its pathogenic implications,
promoter hypermethylation and transcriptional repression
of functionally important cancer-related genes may also
affect tumor behavior, impacting clinical outcomes. Epige-
netic silencing of genes that determine tumor invasiveness,
growth patterns, and apoptosis, in particular, may dictate
tumor recurrence after treatment and impact OS. Because
each tumor may harbor multiple genes susceptible to pro-
moter hypermethylation, individual tumors exhibit differ-
ent frequencies of hypermethylation profile potentially
predictive of a patient’s clinical outcome.8,22 This methyl-
ation profile could be of relevance in those tumors in which
clinical and biologic features of prognostic importance are
not easily available, as in T-ALL.
Our results indicate that methylation of multiple genes
is a common phenomenon in T-ALL and may be the most
important way to inactivate cancer-related genes in this
disease; 88% of patients had at least one gene methylated,
whereas 76% of patients had three or more genes methyl-
ated. No significant differences were found in the CIMP of
Table 3. Methylation Profile in ALL
Feature T-ALL (%) B-ALL (%) P
Methylated genes
ADAMTS1 43 45 NS
ADAMTS5 57 54 NS
APAF-1 40 34 NS
ASPP-1 34 18 .01
CDH1 47 40 NS
CDH13 43 40 NS
DAPK 7 12 NS
DIABLO 32 24 NS
DKK-3 40 32 NS
LATS-1 40 33 NS
LATS-2 26 29 NS
NES-1 59 55 NS
P14 27 19 NS
P15 18 20 NS
P16 15 15 NS
P57 27 18 NS
P73 26 18 NS
PARK-2 37 27 NS
PTEN 20 18 NS
sFRP-1 51 45 NS
sFRP-2 33 8 .001
sFRP-4 20 22 NS
sFRP-5 40 28 .05
SHP-1 17 11 NS
SYK 49 8  .0001
TMS-1 11 7 NS
WIF-1 53 26 .005
Methylation profile
CIMP patients, overall 24 40 .03
CIMP patients, children 25 57 .005
CIMP patients, adults 20 31 .05
Abbreviations: ALL, acute lymphoblastic leukemia; T, T-cell; B, B-cell;
CIMP, patients with zero to two CpG island methylated genes; NS,
not significant.
Fig 1. Aberrant promoter methylation of different genes in T-cell acute
lymphoblastic leukemia (T-ALL). C, human male genomic DNA universally
methylated for all genes (used as a positive control for methylated alleles);
W, blank control without DNA added; UM, unmethylated alleles; M, meth-
ylated alleles.
Methylation Profile in T-ALL
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childhood and adult T-ALLs, suggesting that methylation
status inT-ALL is not age related. This is in contrastwith the
results reported in B-ALL, where adult patients were more
frequently CIMP than children.8 This different epigenetic
map in both ALL subtypesmay have a role in explaining the
prognostic importance of age in B-ALL but not in T-ALL.
Furthermore, the high frequency of genes simultaneously
methylated in T-ALL suggests that CpG island methylation
is related to specific methylation defects in subsets of
T-ALLs, rather than that methylation of each individual
island represents a random event followed by selection for
the affected cell.
Our data also show that the methylation in human
T-ALL cells can participate in the inactivation of the follow-
ing three key cellular pathways: (1) growth-deregulating
events comprising those that target the principal late-G1
cell-cycle checkpoint either directly (p15, p16, and p57 in-
activation) or indirectly (p73, PTEN, NES-1, and LATS-2
inactivation) and those that regulate the G2-M transition
downregulating CDC2/cyclin A kinase activity (LATS-1);
(2) the apoptotic program through inactivation of p14,
TMS1, APAF-1, DIABLO, and DAPK; and (3) the cell-cell
adhesion by the inactivation of some members of the
cadherin (CDH13 andCDH1) andmetalloprotease (ADAMTS1
and ADAMTS5) families. Because the frequencies of meth-
ylation of these genes were similar in T- and B-ALL, one
could speculate that the disruption of these oncogenic path-
ways is a common phenomenon in all types of lymphoid
leukemogenesis. However, a group of five genes (SYK-1,
ASPP-1, sFRP-2, sFRP-5, and WIF-1) showed specificity
for T-ALL, suggesting that they play an important role in
T-cell–lineage leukemogenesis.
Patients with T-ALL who experienced relapse had a
poor outcome. It would be beneficial to identify high-risk
T-cell patients at diagnosis or soon thereafter to modify
their initial therapy with the goal of preventing treatment
failure. However, conventionally applied epidemiologic
features fail to identify these patients. There are no signifi-
cant differences in event-free survival for T-ALL patients
based on age, presenting leukocyte blood cell count, sex,
CNS involvement, or presence of a mediastinal mass.1-4
Thus, novel prognostic factors need to be identified in pa-
tients with T-ALL.
Early response measures may be useful in differentiat-
ing good- and poor-risk T-ALL patients. Initial response to
prednisone prophase is one such predictor. For example, on
a protocol conducted by the Berlin-Frankfurt-Muenster
group, the event-free survival of T-ALL patients with a
favorable prednisone response (78%) was superior to the
event-free survival of patients with a poor response
(32%).25 Levels of minimal residual disease may also
provide useful prognostic information. Cave et al26 re-
ported that high levels of minimal residual disease at the
end of induction therapy correlated with risk of relapse
in T-ALL patients. In addition, expression of oncogenic
Table 4. Multivariate Cox Model for Disease-Free Survival and
Overall Survival in T-ALL
Feature
Univariate Analysis
P
Multivariate Analysis
P
Disease-free survival
Methylation profile .001 .05
WBC  50,000 L .208 —
Age  15 years .460 —
Immunologic subtype .520 —
Overall survival
Methylation profile .006 .02
WBC  50,000 L .04 .10
Age  15 years .66 —
Immunologic subtype .71 —
Abbreviation: T-ALL, T-cell acute lymphoblastic leukemia.
Fig 2. Kaplan-Meier survivor function for T-cell acute lymphoblastic leuke-
mia patients. (A) Disease-free survival (DFS) and (B) overall survival (OS)
curves for all the patients enrolled onto the study according to the methyl-
ation profile. Log-rank test was highly significant for both DFS (P  .0006)
and OS (P  .003). CIMP, CpG island methylator phenotype; CIMP,
patients with zero to two methylated genes (n  12); CIMP, patients with
 2 methylated genes (n  38).
Roman-Gomez et al
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transcription factors, such asHOX11/HOX11L2,27,28 and
studies of gene expression profiles may potentially iden-
tify biologically distinctive, prognostically significant
subsets of patients with T-ALL, as well as potential tar-
gets for novel therapies.29
Complementing these studies, we have shown that ab-
errantmethylation ofCpG islands is quantitatively different
in individual tumors within the same tumor type, and this
patient-specific methylation profile provides important
prognostic information in T-ALL patients. The presence in
individual tumors of multiple epigenetic events that affect
each of the pathways discussed earlier is a factor of poor
prognosis in T-ALL. Patients with methylation of three or
more genes had a poorerDFS andOS thanpatientswith two
or less methylated genes. Multivariate analysis confirmed
that methylation profile was associated with a shorter DFS
andOS. Therefore,methylation profiling inT-ALL could be
clinically important for guiding the selection of therapy and
also providing a basis for developing novel therapies, such
as demethylation treatment. Because the number of sam-
ples analyzed in our study was relatively small, our results
should be independently confirmed in larger series.
In summary, our results indicate that simultaneously
aberrant methylation affecting key molecular pathways is a
common phenomenon in T-ALL. The methylation profile
seems to be an important factor in predicting the clinical
outcome of T-ALL patients.
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